In the current study, a highly porous β-CD-metal organic frameworks (βCD-MOFs) was prepared and drug, olaparib (OP) was loaded successfully in order to enhance the efficacy of OP for the treatment of cervical cancer. The produced OP-loaded βCD-MOFs were assessed using TC-1 cell lines for drug encapsulation, FTIR, DSC, TGA, PXRD, in vitro release studies, SEM, and MTT assay. βCD-MOFs successfully encapsulated the OP with a high efficiency of 76.48%, due to structural advantages of βCD-MOFs. In-vitro release studies exhibited a sustained release pattern for 24 h. As compared to free-OP, we observed a significant reduction in cell viability and lowered inhibitory concentration IC50 (13.52 nM) in TC-1 cells treated with OP-loaded βCD-MOFs. Additionally, p53 and caspase 9 were elevated by the OP-loaded βCD-MOFs, suggesting an effective apoptosis that may hold promise for the therapy of cervical cancer. Overall, OP-loaded βCD-MOFs could be alternative to conventional formulation of OP in treating cervical cancer.
Alsulays et al. (Tue,) studied this question.